Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy.

Authors

Edwin Lam, Thomas Jefferson UniversityFollow
Yi Ting Kayla Lien, University of Florida
Walter K. Kraft, Thomas Jefferson UniversityFollow
Beth Piraino, University of Pittsburgh
Valvanera Vozmediano, University of Florida
Stephan Schmidt, University of Florida
Jingjing Zhang, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

2-17-2020

Comments

This article is the authors' final version prior to publication in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, February 2020.

The published version is available at https://doi.org/10.1177/0896860819889774. Copyright © Sage

Abstract

Intraperitoneal vancomycin is the first-line therapy in the management of peritoneal dialysis (PD)-related peritonitis. However, due to the paucity of data, vancomycin dosing for peritonitis in patients on automated peritoneal dialysis (APD) is empiric and based on clinical experience rather than evidence. Studies in continuous ambulatory peritoneal dialysis (CAPD) patients have been used to provide guidelines for dosing and are often extrapolated for APD use, but it is unclear whether this is appropriate. This review summarizes the available pharmacokinetic data used to inform optimal dosing in patients on CAPD or APD. The determinants of vancomycin disposition and pharmacodynamic effects are critically summarized, knowledge gaps explored, and a vancomycin dosing algorithm in PD patients is proposed.

Recommended Citation

Lam, Edwin; Lien, Yi Ting Kayla; Kraft, Walter K.; Piraino, Beth; Vozmediano, Valvanera; Schmidt, Stephan; and Zhang, Jingjing, "Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy." (2020). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 118.
https://jdc.jefferson.edu/petfp/118

PubMed ID

32065053

Language

English